Three Months Ended Sept 30, 2006
Adjusted
GAAP Adjustments Earnings
Revenues:
Product sales $300,881 $- $300,881
Alliance and development revenue 31,489 - 31,489
Other revenue - - -
Total revenues 332,370 - 332,370
Costs and expenses:
Cost of sales 89,578 (10,010) (b)(d) 79,568
Selling, general and administrative 88,695 (9,708) (d)(g) 78,987
Research and development 39,969 (1,300) (d) 38,669
Write-off of acquired IPR&D - - -
Earnings from operations 114,128 21,018 135,146
Interest income 6,782 - 6,782
Interest expense (1,090) - (1,090)
Other income (expense), net (42,865) 42,389 (h) (476)
Earnings before income taxes and
minority interest 76,955 63,407 140,362
Income tax expense 24,194 22,509 (i) 46,703
Minority interest - - -
Net earnings from continuing
operations 52,761 40,898 93,659
Loss from discontinued operations, net
of taxes - - -
Net earnings $52,761 $40,898 $93,659
Diluted
Earnings per common share - continuing
operations
'/>"/>
| SOURCE Barr Pharmaceuticals, Inc. Copyright©2007 PR Newswire. All rights reserved |